CAR T therapy targeting CD20 for B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new type of CAR T cell therapy that targets the CD20 protein on B-cell lymphoma cells. It is for people with certain types of B-cell lymphoma that have not responded to at least two previous treatments and who cannot use or have already tried the approved CD19 CAR T therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of B-cell lymphoma that has come back or has not responded to treatment (relapsed or refractory DLBCL, mantle cell lymphoma, or indolent lymphoma).
- You have already tried at least two previous treatments, and there is no standard treatment that can cure your lymphoma now.
- You are not able to receive approved CD19-targeted CAR T therapy, or your lymphoma does not have the CD19 marker, or your lymphoma came back after CD19 CAR T therapy.
- You have at least one measurable lymphoma spot on a scan.
- Your overall health is good enough (ECOG score 0-2), and your blood counts, kidney, liver, heart, and lung functions are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of CAR T-cell therapy that targets three proteins (CD19, CD20, and CD22) on lymphoma cells. It's for people with B-cell lymphomas that have come back or not responded to at least two prior treatments.
This study tests a new kind of CAR-T cell therapy for people with certain types of B-cell lymphoma that have come back or not improved after standard treatments. The CAR-T cells have been modified to turn off two genes (BCOR and ZC3H12) to make them work better against the cancer.
This Phase 1 study tests lab-made immune cells (CAR T-cells) that target CD19, CD20, and/or CD22 in people with certain relapsed or refractory B-cell cancers. It may help by attacking cancer cells that still carry these targets, but eligibility is very specific and includes prior treatments and health/lab requirements.
This early-stage study tests a new type of immune cell therapy (CAR-T) that targets two proteins, CD19 and CD20, on your lymphoma cells. It is for people with aggressive B-cell lymphoma that has returned or not responded after several treatments. The goal is to see if this therapy can help shrink the cancer.
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
This trial tests a new type of CAR T-cell therapy that targets two proteins (CD20 and CD19) on your cancer cells. It is for people with certain types of lymphoma that have not responded to or have come back after at least two prior treatments.
Hear when a new Lymphoma, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.